Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/38657
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHutton H.L.en
dc.contributor.authorDjurdjev O.en
dc.contributor.authorBarbour S.J.en
dc.contributor.authorTang M.en
dc.contributor.authorLevin A.en
dc.contributor.authorGill J.en
dc.date.accessioned2021-05-14T13:11:42Zen
dc.date.available2021-05-14T13:11:42Zen
dc.date.copyright2017en
dc.date.created20170410en
dc.date.issued2017-04-10en
dc.identifier.citationBMC Nephrology. 18 (1) (no pagination), 2017. Article Number: 95. Date of Publication: 20 Mar 2017.en
dc.identifier.issn1471-2369 (electronic)en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/38657en
dc.description.abstractBackground: Patients with chronic kidney disease (CKD) due to glomerulonephritis (GN) are thought to be at high risk for cardiovascular disease (CVD). However, no study has examined whether GN directly contributes to CV risk beyond the effects conferred by pre-existing traditional risk factors and level of renal function. Method(s): Matched cohort study using the previously described prospective CanPREDDICT study cohort. 2187 patients with CKD (eGFR 15-45 ml/min/m2) from 25 Canadian centres were divided into GN vs non-GN cause of CKD. Patients on immunotherapy for GN were not included in the study. Standardized measures of CV risk factors, biomarkers and CV outcomes were recorded over 3 years of follow-up, with the primary outcome measure being time to first all-cause CV event. Result(s): In the overall cohort, CV events occurred in 25 (8.7%) of the GN group and 338 (17.8%) of the non-GN group (HR 0.45, 95% CI 0.30-0.67, p < 0.01). In a Cox regression multivariable model that included age, sex, prior diabetes and CVD, baseline eGFR and onset of renal replacement therapy, the risk of CV events was similar in the GN and non-GN groups (HR 0.71, 95% CI 0.47-1.08, p = 0.11). GN and non-GN patients were matched by age and using a propensity score including sex, prior diabetes and CVD and baseline eGFR. In the matched group, the risk of CV events was similar in GN vs non-GN patients (N = 25/271 (9.2%) in both groups, HR 1.01, 95% CI 0.05-1.77, p = 0.9). An interaction analysis showed that CRP, ACR and troponin conferred differing amounts of CV risk in the GN and non-GN groups. Conclusion(s): Patients with advanced CKD due to GN have a high 8.7% absolute 3-year risk of CVD, attributable to prior CV risk factors and level of kidney function rather than the GN disease itself.Copyright © 2017 The Author(s).en
dc.languageenen
dc.languageEnglishen
dc.publisherBioMed Central Ltd. (E-mail: info@biomedcentral.com)en
dc.relation.ispartofBMC Nephrologyen
dc.titleCardiovascular risk is similar in patients with glomerulonephritis compared to other types of chronic kidney disease: a matched cohort study.en
dc.typeArticleen
dc.type.studyortrialObservational study (cohort, case-control, cross sectional or survey)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1186/s12882-017-0511-zen
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid28320366 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28320366]en
dc.identifier.source614884668en
dc.identifier.institution(Hutton) Centre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia (Hutton) Dept of Nephrology, Monash Health, 246 Clayton Rd., Clayton, VIC 3168, Australia (Levin, Gill, Barbour) Division of Nephrology, University of British Columbia, Vancouver, BC, Canada (Levin, Djurdjev, Tang, Barbour) BC Provincial Renal Agency, Vancouver, BC, Canada (Levin, Gill, Barbour) Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, BC, Canadaen
dc.description.addressH.L. Hutton, Centre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia. E-mail: holly.hutton@monash.eduen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2017 Elsevier B.V., All rights reserved.en
dc.subect.keywordsCardiovascular disease Chronic kidney disease Glomerulonephritisen
dc.identifier.authoremailHutton H.L.; holly.hutton@monash.edu Djurdjev O.; ODjurdjev@phsa.ca Tang M.; MxTang@providencehealth.bc.ca Levin A.; alevin@providencehealth.bc.ca Gill J.; JAGill@providencehealth.bc.ca Barbour S.J.; Sean.Barbour@vch.caen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeArticle-
Appears in Collections:Articles
Show simple item record

Page view(s)

28
checked on Feb 7, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.